AKT1 and hepatocellular carcinoma: In hepatocellular carcinoma, sCLU was found to induce resistance to the chemotherapeutic oxaliplatin via activation of the phosphoinositide-3-kinase–protein kinase B (PI3K)/Akt pathway [91] (Fig. 1).